We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Authorized Generics Under Scrutiny By The FTC

Law360 (March 31, 2006, 12:00 AM EST) -- With the debate over authorized generics heating up in recent months, this week’s move by the Federal Trade Commission to determine whether the practice violates anticompetitive guidelines could have wide-ranging effects on the pharmaceutical industry, experts say.

Among the largest generic drug makers slated for FTC scrutiny are Andrx Corp. and Teva Pharmaceutical Industries Ltd., both of which have recently been engaged in high-profile battles with brand-name companies over authorized generics.

Teva’s role in the probe may be especially significant in light of the company’s $7.4...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.